Brampton woman denied OHIP coverage for life-saving cancer drugs Caledon Enterprise The other drug, Rituximab, is approved for second line use, but only in tandem with Fludarabine — a drug that Mitchell can't take because she suffered an extreme, adverse reaction to it during her first bout with chemotherapy. “The drugs that my ... |
